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International pilot study of schizophrenia
(IPSS): Agra centre, India

! Multicentre, WHO at 2 and 5 years
! 76% followed at 2 years (n=1,202)
! Consistent finding at 2 and 5 years was that

schizophrenia in developing countries has better
outcome
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Indian Council of Medical Research (ICMR)

Government of India multicentre study on
course and outcome of schizophrenia
! Time spent in psychotic state

– 15% or less: 62%; 75% or more: 4%
! Best pattern of course: 45%; worst course: 10%
! Impairment of occupational functioning

– nil: 40%; severe: 18%
! Social impairment

– nil: 34%; severe: 12 %
! Overall outcome

– favourable: 66%; intermediate: 30%;
unfavourable: 4%
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Complete Remission as Outcome status in Schizophrenia

‘Real World’ Comparison of First- and Second- Generation Antipsychotics in
Regard to Length of Inpatient Hospitalization and Number of Rehospitalizations( 2008)
1994 & 2004
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Antipsychotics

Whether to treat schizophrenia with
antipsychotic? Banglore Study
! OBJECTIVE: To compare disability in schizophrenia patients

receiving antipsychotics and untreated
! Untreated: unchanged Mean disability scores
! Continued to receive and initiated APD: showed a significant

decline disability.
! The proportion of patients classified as 'disabled' declined
significantly in the treated group (P < 0.01), but remained the
same in the untreated group

Thirthalli J, Venkatesh BK, Kishorekumar KV, Arunachala U, Venkatasubramanian G, Subbakrishna DK,
Gangadhar BN.
Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia
patients.
Acta Psychiatr Scand. 2009 Mar;119(3):209-17
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Treatment effectiveness in
Schizophrenia ( World Health report 2001,
WHO)
% of relapse after 1 Year
Chlorpromazine + family
Therapy- Max.

23

Chlorpromazine + family
Therapy- Min

2

Chlorpromazine- Max

25

Chlorpromazine- Minimum

20

Placebo
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40
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Dixon LB, Lehman AF (1995). Family interventions for schizophrenia. Schizophrenia Bulletin, 21(4): 631–
643.
Dixon LB et al. (1995). Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin,
21(4): 567–577.

CATIE – Phase 3, Symptom
response
Drugs

ARIP

CLOZ

COM
B

FLU-D

OLAN

PERP

QUET

RISP

ZIPR

Pvalue

PANSS
–3
months

0.506

0.002
!

0.002

0.005
!

0.002
!

0.084

0.013

0.044

0.045

0.832
"

PANSS
-6

<0.00
1
##

0.006

<0.00
1
#

0.43

0.003
#

0.018

0.100

0.009

0.371

0.515
"

5

What is the prescribing pattern
SGAs have become the first-line treatment for psychiatric disorders.
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‘Real World’ Comparison of First- and Second- Generation
Antipsychotics in Regard to Length of Inpatient Hospitalization and
Number of Re-hospitalizations( 2008)
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150 DB, N= 21 533,
4 Drugs amisulpride clozapine, olanzapine risperidone
were better than FGA, with small to medium ES.:

The other SGA were not more efficacious than the
FGA, even for negative symptoms.
With the exception of aripiprazole and ziprasidone,
SGA drugs induced more weight gain

The CATIE and CUtLASS studies in schizophrenia: results
and implications for clinicians.
! CATIE and CUtLASS suggest that SGAs do not live up to all the previous

expectations.
! However, even if most of these advantages are debatable, the lower risk of

Tardive dyskinesia and the better subjective effects should be strong enough
reasons to favour these drugs.
! There is no single antipsychotic that is best for every schizophrenia patient,

as individual responses differ markedly.
! For successfully individualized treatment, a multitude of antipsychotic options

are needed.

Naber D, Lambert M.The CATIE and CUtLASS studies in schizophrenia: results and implications for
clinicians.
CNS Drugs. 2009 Aug 1;23(8):649-59.
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Lessons to take home from CATIE.
! Rather than selecting drugs on the basis of unfounded expectations of

superior efficacy, clinicians can focus on selecting drugs and optimizing
dosages to minimize adverse effects without sacrificing efficacy.
! Tardive dyskinesia may be a good reason to avoid a high dosage of first-

generation antipsychotics,
! although the evidence for differential risk is less compelling for a modest

dosage of low-affinity first-generation antipsychotics.
! Similarly, the metabolic effects of some second-generation antipsychotics can

be decisive in considering risks.
! In either case, the clinician should detect earliest signs and take action while

dyskinetic or metabolic effects are most reversible.
Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv.
2008 May;59(5):523-5.

Bottom line: the dichotomy between first- and
second-generation antipsychotics was not
supported by efficacy data (and now, is not
supported effectiveness data).
Only clozapine has documented superiority in
treatment-resistant cases.

Lessons to take home from CATIE.
Carpenter WT, Buchanan RW. Lessons to take home
from CATIE. Psychiatr Serv. 2008 May;59(5):523-5.
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INTRODUCTION
• Antipsychotic medications form the mainstream of

treatment in schizophrenia
• These drugs have several short term as well long term

advantages
• It is not known if atypical antipsychotics have the long-

term effect of improving outcome and meeting
expectations (1,2,3)
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The present study examined the usage
of antipsychotics drugs and their
associations with clinical outcome in a
long-term naturalistic study

METHODS AND MATERIALS
! • First episode hospitalized schizophrenia patients (diagnosed

according to DSM-IIIR criteria) were followed for ten years
! • After ten years, diagnosis was re-confirmed (using DSM-IV

criteria) and outcome was assessed
! • Outcome was assessed using Clinical Global Impression Scale

(CGIS)
! • CGIS scores were correlated with key antipsychotic drugs used

in the preceding 12 months
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Multiple outcome criteria in
schizophrenia
Thirteen criteria
! Psychopathology (positive symptoms, negative

symptoms and disorganisation)
! Cognitive function (attention, executive function,

working memory, recall memory, semantic memory,
storage memory)
! Interpersonal social function
! Work–school function
! Extrapyramidal function (parkinsonism, akathisia,

tardive dyskinesia)
Meltzer HY. Eur Psychiatry 1995;10(Suppl. 1):19S–25S

Multiple outcome criteria in
schizophrenia (cont’d)
! Independent living
! Aggression
! Quality of life
! Compliance
! Hospitalisation
! Family burden
! Social burden
! Suicidality
Meltzer HY. Eur Psychiatry 1995;10(Suppl. 1):19S–25S
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Re-assessed outcome at 10 years

Global Social outcome

12

RESULTS
! Only 62.6% improved significantly in a cohort of

101 patients after ten years
! 85% patients were maintained on atypical
antipsychotics
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Percentage usage pattern and per day mean dosage
in mg at end point:

Cognition
! Significant decrease in visuo-spatial function.
! (p=.002, Paired t),
! % of patients with abnormal value on BG increased but

not significantly (p=.114, McNemar’s Chi-square test)
! Memory decreased (WMS) significantly (p=.003, Paired
t)
! % of patient with abnormal values increased but not
significantly (p=.144, McNemar’s Chi-square test)
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Correlation between BG & WMS (Cognition) at
Baseline and other Baseline Variables
Correlation between BG & WMS (Cognition) at Baseline and other Baseline Variables
BG

WMS

r

P

r

P

PANSS

-0.210

.104

0.204

.115

NS

0.070

.593

-0.164

.206

PS

-0.006

.966

-0.150

.249

Duration

-0.051

.695

0.350

.006

Age at Intake

-0.014

.918

-0.088

.504

Sex

.243

.059

-0.047

.717

Association between Baseline Cognition (BG/WMS)
and outcome parameters at 10 Year Outcomes
Association between Baseline Cognition (GB/WMS) at baseline and 10 Year Outcomes
BG

WMS

10 Year
Outcomes

Parameter
Estimate
(se)

P value

Parameter
Estimate
(se)

P value

PS

-0.042 (0.037)

.260

0.012 (0.039)

.766

NS

-0.052 (0.072)

.474

-0.029 (0.076)

.699

GP

0.133 (0.122)

.279

0.087 (0.129)

.503

HDRS

0.071 (0.054)

.196

-0.079 (0.054)

.146

GAF

0.176 (0.117)

.137

0.045 (0.124)

.721

QOL

-0.203 (0.109)

.067

0.112 (0.116)

.340

CGIS-I

0.0005 (0.0048) .913

0.004 (0.005)

.487
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Conclusion
Long-term Outcome of first episode
schizophrenia does NOT differ across
atypical antipsychotics

What decides quality of life of patients with
schizophrenia?
Comorbid
Substanc
e abuse

Nature of
illness &
Duration

Quality of
treatment &
Accessibilit
y

Comorbid
physical
illness

Mental
Health
Facilities

QO
L

Side
effects :
TD,
Weight

Level of
Disability

EE &
family
Support

Psychosoci
al support
Psychosoci
al
intervention
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Pathway for poor Outcome

Cognitive
dysfunction
Poor Social
Functioning
and
Integration

Loss Of
Insight

Relapse

Poor
awareness
Drug
Discontinuation

Weiden et al. Psych Services, 2004

Determinants of outcome in schizophrenia
Patient

environment

Illness

Outcome

Nature of
Treatment

Family

Setting of
treatment
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Illness Related
–
–
–
–
–
–
–
–
–
–
–
–
–
–

illness loses its intensity [Dube K.C]
definitions did not reveal significant variability [, Kulhara.P]
Short duration of illness [vergese.et al]
longer time spent in psychosis [Thara R]
short-term course [Varma V.K.]
Sexual, religious and grandiose delusions and flat affect [Thara, R]
DUP, [Tirupati,, Yanos PT]
Relapse [Yanos PT]
Comorbidity
negative syndrome
cognitive functioning [Altamura AC]
Premorbid level of functioning
violence,
severity of illness [Wittorf A]

Patient related
– absence of economic difficulties, Verghese A
– increase in religious activities Verghese A
– a non-schizoid pre-morbid personality [Verghese A]
– Male [ DubeK.C.]
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Family related
– Positive attitudes of relatives and neighbours,
[Verghese A]
– EE
– Psycho-education [ Kulhara P.]

Treatment related ( nature)
– consistent compliance
– Reduced levels of membrane essential
polyunsaturated fatty acids (EPUFAs),[ Arvindakshan
M,
– Rehabilitation [Chatterjee S]
– limited efficacy for specific domains of
psychopathology of current treatments; [Yanos PT]
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Treatment settings
– Developing country , [Dube.K.C., Varma.V.K.
Dragomirecká E, Patel V, Kulhara.P
– Rural background, (Verghese A]

Environment related
– Mean environmental temperature [Gupta,S
– Bias [Thirthalli J]
– Transcultural factors [Kulhara.P]
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Measures to maximise the outcome
! Early psychosis programme
! Cognitive enhancement and preservation
! Improvising insight, awareness and compliance
! Minimising EPS
! Minimising drop-outs and discontinuation
! Psycho-education
! Psychosocial intervention
! Cognitive behavioural
! Minimising hospital stay
! Relapse prevention
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